When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Leprosy

Evidence last reviewed: 15 Feb 2026
Topic last updated: 10 Nov 2022

Summary

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • presence of risk factors
  • typical skin lesions
  • nerve involvement
  • sensory loss
Полная информация

Другие диагностические факторы

  • immunological reactions
  • eye lesions
Полная информация

Факторы риска

  • close contact with a person with multibacillary leprosy
  • poverty
  • residence in endemic area
  • genetic predisposition
  • zoonotic transmission
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • skin smear
  • skin and/or nerve biopsy and histopathology
Полная информация

Исследования, проведение которых нужно рассмотреть

  • polymerase chain reaction
Полная информация

Алгоритм лечения

Острый

multibacillary (MB) or paucibacillary (PB): no rifampicin or fluoroquinolone resistance

multibacillary (MB) or paucibacillary (PB): rifampicin ± fluoroquinolone resistance

ПРОДОЛЖЕНИЕ

type 1 reaction (reversal reaction)

type 2 reaction (erythema nodosum leprosum)

Lucio's phenomenon

Составители

Авторы

Maria T. Ochoa, MD

Clinical Professor of Dermatology

USC Keck School of Medicine

Department of Dermatology

Los Angeles

CA

Раскрытие информации

MTO declares that she has no competing interests.

Выражение благодарностей

Dr Maria T. Ochoa would like to gratefully acknowledge Dr Denis Paul Jacques Daumerie, a previous contributor to this topic. DPJD declares that he has no competing interests.

Рецензенты

Hubert Sansarricq, MD

Member of World Health Organization Panel of Experts on Leprosy

Saint-Armour Morlaas

France

Раскрытие информации

HS declares that he has no competing interests.

David M. Scollard, MD, PhD

Chief

Clinical Branch

National Hansen's Disease Programs

Baton Rouge

LA

Раскрытие информации

DMS declares that he has no competing interests.

Alexandre Tiendrebéogo, MD, MPH

Medical Officer

Leprosy and Neglected Tropical Diseases in Central Africa Countries

World Health Organization

Country Office of Kinshasa

DR of Congo

Раскрытие информации

AT declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

World Health Organization. Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021-2030. Apr 2021 [internet publication].Full text

World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68.Full text

World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Oct 2018 [internet publication].Full text

World Health Organization. Leprosy/Hansen disease: management of reactions and prevention of disabilities. 2020 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას